House Publications
The Debates are the report—transcribed, edited, and corrected—of what is said in the House. The Journals are the official record of the decisions and other transactions of the House. The Order Paper and Notice Paper contains the listing of all items that may be brought forward on a particular sitting day, and notices for upcoming items.
For an advanced search, use Publication Search tool.
If you have any questions or comments regarding the accessibility of this publication, please contact us at accessible@parl.gc.ca.
|
|
|
Notice PaperNo. 242 Monday, October 30, 2023 11:00 a.m. |
|
|
|
|
Introduction of Government Bills |
|
Introduction of Private Members' Bills |
|
Notices of Motions (Routine Proceedings) |
|
Questions |
|
| Q-19482 — October 27, 2023 — Mr. Aitchison (Parry Sound—Muskoka) — With regard to the Housing Accelerator Fund: (a) from which municipalities has the government received action plans; (b) of the action plans in (a), which ones are (i) accepted, (ii) rejected, (iii) still under consideration; (c) broken down by each municipality, how much funding will they be eligible for once their plan is approved; (d) which municipality has received funding to date and how much has each municipality received; and (e) what is the total amount disbursed from the Fund to date? |
| Q-19492 — October 27, 2023 — Mr. Shipley (Barrie—Springwater—Oro-Medonte) — With regard to the program Reaching Home: Canada’s Homelessness Strategy, administered by Infrastructure Canada and formerly by Employment and Social Development Canada, since the program’s inception in 2019: (a) how many individuals have been lifted out of (i) homelessness, (ii) chronic homelessness, as a result of the program, in total, and broken down by year; (b) how much funding has been dispersed through the strategies, in total, and broken down by entity receiving the funding; (c) how much funding did each entity in (b) receive; (d) how many employees or full-time equivalents are assigned to work on this program; (e) were there any outside consultants hired to work on this program, and, if so, what were the details of each contract, including the (i) vendor, (ii) amount, (iii) date, (iv) description of the goods or services provided, including the scope of work; and (f) what performance metrics have Infrastructure Canada and Employment and Social Development Canada used to evaluate the success of this program and how do the results compare? |
| Q-19502 — October 27, 2023 — Mr. Ellis (Cumberland—Colchester) — With regard to the Canadian Armed Forces (CAF): what is the breakdown of the religions or denominations that CAF members identify as, in total, and broken down by branch of the CAF, including the number and percentage of CAF members for each? |
| Q-19512 — October 27, 2023 — Mr. Berthold (Mégantic—L'Érable) — With regard to the current backlog at Immigration, Refugees, and Citizenship Canada (IRCC) related to the designated lines and inquiry options for members of Parliament, broken down by month for the last two years: (a) how many members offices made inquiries about cases; (b) how many cases were represented by the inquiries in (a); (c) what was the average time between when an inquiry was made by a member of Parliament and a decision was made by IRCC; (d) what was the average backlog, either in time spent on hold, or the wait time before an appointment was available for members offices attempting to present cases to IRCC; and (e) what is the current backlog of cases involving inquiries by members of Parliament? |
| Q-19522 — October 27, 2023 — Mr. Dreeshen (Red Deer—Mountain View) — With regard to usage of the government's fleet of Challenger aircraft, since September 1, 2023: what are the details of the legs of each flight, including the (i) date, (ii) point of departure, (iii) destination, (iv) number of passengers, (v) names and titles of the passengers, excluding security or Canadian Armed Forces members, (vi) total catering bill related to the flight, (vii) volume of fuel used, or an estimate, (viii) amount spent on fuel? |
| Q-19532 — October 27, 2023 — Mr. Duncan (Stormont—Dundas—South Glengarry) — With regard to Sustainable Development Technology Canada (SDTC): what specific interests and potential conflicts were identified in the ethical disclosures for each member of SDTC’s executive team, broken down by individual? |
| Q-19542 — October 27, 2023 — Mr. Carrie (Oshawa) — With regard to Health Canada’s (HC) approval of the Pfizer/BioNTech COVID-19 vaccines: (a) did Pfizer disclose that Process 1 vaccine formula was used during the original trial to obtain their safety and efficacy data while Process 2 was invoked following Interim Order to massively upscale production of vaccine doses whereby DNA was cloned into a bacterial plasmid vector for amplification in Escherichia coli (E. coli) before linearization with the possibility of potential residual DNA; (b) was HC aware of the quantum of linearized DNA fragments present in each dose of the Pfizer vaccine prior to releasing the vaccine to Canadians, and, if so, what was the amount of acceptable residual DNA per vaccine dose and the method used to measure it; (c) if the response to (b) is negative, has HC since confirmed the quantum of linearized DNA per vaccine dose per mRNA manufacturer, and, if so, what method was used; (d) do the risks of residual DNA meet HC’s standards for transfected foreign DNA; (e) did Pfizer and BioNTech disclose to HC the presence of the Simian Virus 40 (SV40) promoter-enhancer-ori used to amplify the production of Spike mRNA in the DNA plasmid used to produce the mRNA; (f) has HC confirmed the presence of SV40 sequences in the Pfizer vaccine, and, if so, is the amount of SV40 within safe limits and how was it tested; (g) if the response to (f) is negative, when and who will conduct the study to confirm the presence of SV40 and by what method; (h) how were contaminants and impurities addressed throughout the regulatory process for both Pfizer/BioNTech and Moderna products; (i) are further studies planned to investigate how these contaminants and impurities will impact human subjects given transfection for both products, and, if so, who will conduct the investigation and when will it be conducted; (j) is HC considering regulating these products as gene therapy products; and (k) how does HC plan to inform those Canadians who received the mRNA products about the adulteration of these products, specifically SV40 in Pfizer and heightened levels of DNA plasmids in both Pfizer and Moderna products, to ensure fully informed consent? |
| Q-19552 — October 27, 2023 — Mr. Berthold (Mégantic—L'Érable) — With regard to the grocery rebate announcement made by the Deputy Prime Minister and Minister of Finance at Rabba Fine Foods in early July 2023: (a) did any of the minister’s staff members remove, or request that the store remove, the price tags from the food in the background of the announcement, and, if so, why was this done; and (b) if the answer to (a) is negative, what is the minister’s explanation as to why there were no prices visible in the background of her announcement? |
| Q-19562 — October 27, 2023 — Mr. Julian (New Westminster—Burnaby) — With regard to fossil fuel subsidies provided by the government since November 1, 2015: (a) how many new subsidies have been established, broken down by (i) year, (ii) dollar amount, (iii) program; and (b) how many existing subsidies have been repealed, expired, or are no longer funded, broken down by (i) year, (ii) dollar amount, (iii) program? |
Notices of Motions for the Production of Papers |
|
Business of Supply |
|
Government Business |
|
Private Members' Notices of Motions |
|
Private Members' Business |
| C-356 — September 20, 2023 — Mr. Poilievre (Carleton) — Second reading and reference to the Standing Committee on Human Resources, Skills and Social Development and the Status of Persons with Disabilities of Bill C-356, An Act respecting payments by Canada and requirements in respect of housing and to amend certain other Acts. |
| Pursuant to Standing Order 86(3), jointly seconded by: |
| Mr. Kmiec (Calgary Shepard) — September 25, 2023 |
| Statement by Speaker regarding royal recommendation — October 19, 2023 (See Debates). |
|
|
|
| 2 Response requested within 45 days |
|